Company intelligence / Profile preview

Wuhan Zhongsheng Yujin Biomedical

Ownership: Private
Development stage: Commercial

Overview

Wuhan Zhongsheng Yujin Biomedical specializes in the production and distribution of blood products, notably anti-human T lymphocyte porcine immunoglobulin. Its lead product has been approved in China since at least the early 1980s for use in preventing and treating transplant rejection. The company operates as a wholly owned subsidiary of the Wuhan Institute of Biological Products, itself part of Sinopharm. Sales data indicate continued commercial activity as recently as 2022–2023.

Therapeutic areas: Immunology
Modalities: ImmunoglobulinBiologic
Industry: Biotech

Drug pipeline

2 assets

porcine anti-human lymphocyte immunoglobulin

Unknown

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Wuhan Zhongsheng Yujin Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Zhongsheng Yujin Biomedical.

Explore the full profile